Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.
Harmen ReyngoudtPierre-Yves BaudinEricky Caldas de Almeida AraújoDamien BachassonJean-Marc BoisserieKubéraka MariampillaiMélanie AnnoussamyYves AllenbachJean-Yves HogrelPierre G CarlierBenjamin MartyOlivier BenvenistePublished in: Journal of cachexia, sarcopenia and muscle (2024)
P MRS can discern measurable differences between placebo and sirolimus-treated IBM patients, offering promise for future therapeutic trials in idiopathic inflammatory myopathies such as IBM.
Keyphrases
- magnetic resonance imaging
- newly diagnosed
- end stage renal disease
- ejection fraction
- prognostic factors
- peritoneal dialysis
- skeletal muscle
- computed tomography
- oxidative stress
- randomized controlled trial
- single molecule
- current status
- patient reported outcomes
- big data
- rheumatoid arthritis
- contrast enhanced
- myasthenia gravis